InVitria

A leader in sustainable and ethical animal-free components used in biomanufacturing and final formulation for cell therapy, gene therapy and vaccines.

[InVitria @InVitria]

LVVs can lose infectious titer during TFF, sterile filtration, freeze-thaw, and process holds.
See how Optibumin® 25 rHSA supported LVV stability and recovery across key DSP stress conditions.
Download the ASGCT 2026 poster: https://t.co/Wh50xQOPYU
#GeneTherapy #LVV

[InVitria @InVitria]

Join InVitria at ASGCT 2026 in Boston to see new data on reduced-DMSO cryopreservation using recombinant albumin.

Mark Stathos, PhD, Applications Scientist at InVitria, will present Poster #2182:
“Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency.”

The poster highlights post-thaw performance data across T cells, MSCs, and iPSCs, including viability, expansion, apoptosis, and pluripotency outcomes under reduced-DMSO conditions.

Stop by Poster #2182 to discuss the data with our team.

#ASGCT2026 #CellTherapy #Cryopreservation #iPSC #MSC #TCells #Bioprocessing #Biomanufacturing

[InVitria @InVitria]

Join InVitria at ASGCT 2026 today as Mark Stathos, PhD presents new data on recombinant animal-free albumin for lentiviral vector manufacturing and downstream processing.

The presentation will highlight how recombinant albumin helped:
• Improve infectious lentiviral vector yields
• Preserve vector titers during sterile filtration
• Support downstream processing and final formulation workflows

📍 Room 162AB
🕓 Today at 4:45 PM
📍 Visit InVitria at Booth #909

Don't forget our POSTER # 2182 on Cryopreservation of Therapeutic Cells using LOWER DMSO!!!!!

#ASGCT2026 #CellTherapy #GeneTherapy #LentiviralVectors #Bioprocessing

[InVitria @InVitria]

Heading to ASGCT 2026? Stop by Booth #909 to meet the InVitria team and learn how recombinant, animal-origin-free proteins are supporting gene and cell therapy workflows.

We’ll also be presenting about how to enhancing infectious lentiviral vector yields.
Title: Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields By Stabilizing Viral Particles During Downstream Processing and Final Formulation.
Presented by Mark Stathos, PhD
📍May 12 at 4:45 PM | Room 162AB

And presenting a poster:
📍#2182
Title: Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency

See how recombinant albumin can support:
• Reduced-DMSO cryopreservation
• Post-thaw recovery
• Cell viability and expansion
• More defined manufacturing workflows

#ASGCT2026 #CellTherapy #GeneTherapy #Bioprocessing #Cryopreservation

[InVitria @InVitria]

Day 2 in Nashville and the booth has been the best seat in the house. 👋

After Scott's talk yesterday on the recombinant albumin journey, the questions kept coming — about Exbumin® for lyophilized formulations, Optibumin® 25 for closed-system GMP workflows, and what it really takes to move away from plasma-derived HSA.

These are our favorite kinds of conversations: real problems, real formulations, real timelines.

If you're at IPEC Excipient World, come find Scott, Elliott and Jake at Booth #328 — we're here through tomorrow. ☕️

#ExcipientWorld #IPEC #RecombinantAlbumin #InVitria

[InVitria @InVitria]

What does it take for a novel excipient to become a standard?

At the Biologics Summit, Scott Deeter broke down the recombinant albumin journey, including:
• Stability and performance considerations
• Regulatory path and adoption barriers
• Real-world use in approved biologics

Relevant for teams working on formulation, process consistency, or risk reduction.
The talk will be posted soon. Visit https://t.co/vA3ruPiFkc to receive it directly
#ExcipientWorld #Biologics #DrugFormulation #Bioprocessing #RecombinantProteins

[InVitria @InVitria]

InVitria is heading to ISCT Annual Meeting.

We’ll be onsite connecting with teams working on cell therapy development and manufacturing.

If you’re attending, plan to meet with
Marcus Curl, VP of Product Applications, and
Jake Hanks, Director of Business Development.

They’ll be discussing how animal-origin-free, chemically defined proteins support:

Consistent cell expansion
Scalable manufacturing
Reduced variability across workflows

If you’re working on process development or scale-up, reach out ahead of the meeting to connect.

#ISCT2026 #CellTherapy #Biomanufacturing #ProcessDevelopment #AOF

[InVitria @InVitria]

Recombinant albumin is already used in approved biologics.

At IPEC Excipient World 2026, we’re sharing how Exbumin® and Optibumin® 25 support:
• formulation stability
• lot-to-lot consistency
• scalable GMP manufacturing

See the full announcement: https://t.co/Ox2v0D9LK2

#Biologics #Biomanufacturing #Excipients #DrugFormulation #RecombinantProteins #IPEC2026

[InVitria @InVitria]

Exploring excipient options? See our portfolio and comparison resources → https://t.co/XkhwaGI1eR

[InVitria @InVitria]

Nashville-bound! 🎸
Catch InVitria at Excipient World 2026, May 4-6 at Gaylord Opryland.

🎤 CEO Scott Deeter presents "From Novel Excipient to Gold Standard: The Recombinant Albumin Journey" — May 4th
📍 Visit us at Booth 328

Elliott Renft & Jacob Weber, PhD will be there too. Let's connect!
#ExcipientWorld2026 #IPEC #Excipients

[InVitria @InVitria]

Today is World Laboratory Day.

Behind every dataset, publication, and therapeutic candidate is a lab making it happen.

At InVitria, we support that work with:

Animal-origin-free recombinant proteins
Consistent, defined materials
Scalable solutions from research to manufacturing

🔗 Learn more: https://t.co/8Hlf9Ekn4Y
Less variability. More confidence in your data.
#WorldLaboratoryDay #CellCulture #Bioprocessing #Biotech #LifeSciences

[InVitria @InVitria]

We've landed in Palma! 🇪🇸 Marcus and Beren are representing us at #TERMIS2026 this week — four days of the best minds in tissue engineering and regenerative medicine working to close the gap in clinical translation.
Attending too? Find us on the floor 👋

[InVitria @InVitria]

At #ALPHA2026, Dean Morbeck highlighted:

Serum albumin → variability
Recombinant albumin → control

Defined systems make these gaps obvious.

The shift is already happening.

#ReproductiveMedicine #Biotech #CellCulture

[InVitria @InVitria]

Our team will be at TERMIS-EU 2026 to focus on the essential role of recombinant proteins in the clinical translation of regenerative medicine. Achieving reproducible results at scale requires a shift away from ill-defined, serum-based supplements toward animal-origin-free, chemically defined systems. We invite you to learn how InVitria’s high-purity raw materials and excipients simplify the regulatory path and ensure the batch-to-batch consistency. Let’s discuss how we can support your transition from bench to clinic.
#TERMIS2026 #TERMISEU #RegenerativeMedicine #TissueEngineering #RegenMed #Biomaterials

[InVitria @InVitria]

InVitria is headed to Alpha 2026 to discuss the critical transition from plasma-derived proteins to chemically defined, recombinant alternatives in reproductive medicine. With high-purity, animal-origin-free components, we enable embryologists to eliminate the lot-to-lot variability and improve outcomes. We look forward to connecting with the scientific community to discuss how these innovations are establishing a new standard for consistency and performance in the modern IVF laboratory.

#Alpha2026 #AlphaScientists #ReproductiveMedicine #IVF #Embryology #FertilityScience

[InVitria @InVitria]

Can you reduce LVV titer loss during filtration?

Data shows:
~75% genomic titer retained vs ~19%
~49% infectious titer retained vs ~17%

See how rHSA pre-coating improves recovery: https://t.co/Xif8AAFH3H

#CellTherapy #CAR-T #LVV

[InVitria @InVitria]

🚨 “Bad lots” of Poloxamer 188 are still killing cell viability & productivity — even after they pass spec. 😤
Synthetic surfactants have one trick. rHSA has three:
• Viscoelastic shear shield
• Cys34 antioxidant power
• Metal sequestration
Result? ~50% ↑ IVCC + 92–140% higher titers. Consistent. Animal-free. Game-changing.
Stop fighting your surfactant. Upgrade to the real deal.
Read why rHSA is the ideal Poloxamer 188 alternative:
https://t.co/VehoC8pvLD
#Biomanufacturing #CellCulture #rHSA #CHO #CellTherapy

[InVitria @InVitria]

Lentiviral titer loss during filtration is a major challenge.

Using recombinant human serum albumin (rHSA), we achieved:
• ~3× higher infectious titer recovery
• Improved LVV retention

Read the full application note: https://t.co/kB6AEJ4jST

#GeneTherapy #CellTherapy #Lentivirus #Bioprocessing #CAR-T

[InVitria @InVitria]

“Bad lots” of poloxamer 188 have caused drops in cell viability and productivity.

And they still passed spec.

That’s the problem.

Here’s what’s behind it: https://t.co/WL578WGHow

#Biomanufacturing #CellCulture #CHO #ProcessDevelopment

[InVitria @InVitria]

If polysorbates introduce instability, why are they still standard?

There’s a more controlled alternative worth looking at.
Read more: https://t.co/sLRpqDMnay

#Biologics #DrugFormulation #Bioprocessing #Pharma